The Efficacy and Safety of Dapagliflozin in Women and Men With Type 2 Diabetes Mellitus: Insights From The DECLARE-TIMI 58 Trial

被引：0
|
作者：
O'Donoghue, Michelle L.
Kato, Eri T.
Mosenzon, Ofri
Murphy, Sabina A.
Cahn, Avivit
Marmolejo, Marisol H.
Tankova, Tsvetalina
Smahelova, Alena
Merlini, Piera A.
Gause-Nilsson, Ingrid A.
Langkilde, Anna Maria
McGuire, Darren K. K.
Wilding, John
Leiter, Lawrence A.
Bhatt, Deepak L.
Raz, Itamar
Sabatine, Marc S.
Wiviott, Stephen D.
机构：
来源：
CIRCULATION | 2019年 / 140卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A10083
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Influence of cardiovascular drugs on the efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
    Oyama, K.
    Raz, I.
    Cahn, A.
    Goodrich, E.
    Bhatt, D.
    Leiter, L.
    McGuire, D.
    Wilding, J.
    Gause-Nilsson, I.
    Mosenzon, O.
    Sabatine, M.
    Wiviott, S.
    [J]. EUROPEAN HEART JOURNAL, 2021, 42 : 2961 - 2961
  • [2] Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial
    Zelniker, Thomas A.
    Bonaca, Marc P.
    Furtado, Remo H. M.
    Mosenzon, Ofri
    Kuder, Julia F.
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Budaj, Andrzej
    Kiss, Robert G.
    Padilla, Francisco
    Gause-Nilsson, Ingrid
    Langkilde, Anna Maria
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. CIRCULATION, 2020, 141 (15) : 1227 - 1234
  • [3] Effect of Dapagliflozin on Atrial Fibrillation/Flutter in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial
    Zelniker, Thomas A.
    Bonaca, Marc P.
    Mosenzon, Ofri
    Kuder, Julia F.
    Murphy, Sabina A.
    Furtado, Remo H.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P.
    Budaj, Andrzej
    Kiss, Robert Gabor
    Padilla, Francisco
    Gause-Nilsson, Ingrid A.
    Langkilde, Anna Maria
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. CIRCULATION, 2019, 140
  • [4] Effect of dapagliflozin on atrial fibrillation/flutter in patients with Type 2 Diabetes mellitus: insights from the DECLARE-TIMI 58 trial
    Zelniker, T.
    Bonaca, M.
    Mosenzon, O.
    Kuder, J.
    Murphy, S.
    Remo, F.
    Deepak, B.
    Leiter, L.
    McGuire, D.
    Wilding, J.
    Budaj, A.
    Kiss, G.
    Padilla, F.
    Gause-Nilsson, I.
    Langkilde, A. M.
    Raz, I.
    Sabatine, M.
    Wiviott, S.
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S158 - S158
  • [5] Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial
    Furtado, Remo H. M.
    Raz, Itamar
    Goodrich, Erica L.
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Aylward, Philip
    Dalby, Anthony J.
    Dellborg, Mikael
    Dimulescu, Doina
    Nicolau, Jose C.
    Oude Ophuis, Anthonius J. M.
    Cahn, Avivit
    Mosenzon, Ofri
    Gause-Nilsson, Ingrid
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. CIRCULATION, 2022, 145 (21) : 1581 - 1591
  • [6] Cardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 Trial
    Oyama, Kazuma
    Wiviott, Stephen D.
    Raz, Itamar
    Cahn, Avivit
    Goodrich, Erica
    Bhatt, Deepak L.
    Leiter, Lawrence
    McGuire, Darren K.
    Wilding, John
    Gause-Nilsson, Ingrid A.
    Mosenzon, Ofri
    Sabatine, Marc S.
    Bohula, Erin A.
    [J]. CIRCULATION, 2020, 142
  • [7] Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
    Cahn, Avivit
    Mosenzon, Ofri
    Wiviott, Stephen D.
    Rozenberg, Aliza
    Yanuv, Ilan
    Goodrich, Erica L.
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Johansson, Peter A.
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Raz, Itamar
    [J]. DIABETES CARE, 2020, 43 (02) : 468 - 475
  • [8] Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial
    Oyama, Kazuma
    Raz, Itamar
    Cahn, Avivit
    Kuder, Julia
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Park, Kyong-Soo
    Goudev, Assen
    Diaz, Rafael
    Spinar, Jindrich
    Gause-Nilsson, Ingrid A. M.
    Mosenzon, Ofri
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 (31) : 2958 - 2967
  • [9] Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial
    Furtado, Remo H. M.
    Bonaca, Marc P.
    Raz, Itamar
    Zelniker, Thomas A.
    Mosenzon, Ofri
    Cahn, Avivit
    Kuder, Julia
    Murphy, Sabina A.
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Ruff, Christian T.
    Nicolau, Jose C.
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. CIRCULATION, 2019, 139 (22) : 2516 - 2527
  • [10] Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study
    Cahn, Avivit
    Raz, Itamar
    Bonaca, Marc
    Mosenzon, Ofri
    Murphy, Sabina A.
    Yanuv, Ilan
    Rozenberg, Aliza
    Wilding, John P. H.
    Bhatt, Deepak L.
    McGuire, Darren K.
    Gause-Nilsson, Ingrid A. M.
    Fredriksson, Martin
    Johansson, Peter A.
    Jermendy, Gyorgy
    Hadjadj, Samy
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    Leiter, Lawrence A.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (08): : 1357 - 1368
12345